RXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Recursion Pharmaceuticals Inc (RXRX) is not a strong buy at the moment for a beginner investor with a long-term perspective. The technical indicators are bearish, options sentiment is neutral, and the company's financial performance shows significant losses despite revenue growth. Analyst ratings have been revised downward, and there are no strong positive catalysts or trading signals to suggest immediate action. Holding or monitoring the stock for better entry points is recommended.
The technical indicators for RXRX are bearish. The MACD is negatively expanding below zero, RSI is neutral at 24.537, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 3.128 and resistance at 3.464.
The company's revenue increased significantly by 681.74% YoY in Q4 2025, showing potential for growth. Additionally, the appointment of a new Chief Medical Officer could bring fresh leadership and strategic direction.
Broader AI sector revaluation and bearish sentiment may also weigh on the stock.
In Q4 2025, the company reported revenue growth of 681.74% YoY, reaching $35.54 million. However, net income dropped to -$108.12 million (-39.56% YoY), and EPS fell to -$0.21 (-60.38% YoY). Gross margin decreased significantly to 59.83 (-132.98% YoY), indicating worsening profitability.
BofA recently lowered the price target for RXRX from $7 to $6 and maintained a Neutral rating. The revision reflects updated estimates, operating expenses, and delayed launch timing for REC-617.
